Opportunity, I certainly did not invest because RECAF was a universal marker. As a matter of fact, I always though that to be a negative aspect since it did not point toward the abnormal cells.
I invested in the stock as Dr. Moro developed the test for the Abbott architect system and my holdings were based upon that test going to trials. We still don't know the reason why Abbott jumped ship but all my research says they should have continued developing the combination of RECAF and PSA because I think the RECAF test works and that test would have been a decent seller.
I have not purchased any stock since the Abbott news but from Dr. Moro's use of cash to pay Smithline, IMO, that third licensee is indeed going to happen so I am not going to sell. A new licensee will remove any stigma of the Abbott deal and we will just press on to approval via IMA, albeit a year later in development.
News 
Market Data 
Discover 
